Seattle’s Impel NeuroPharma bags $67.5M crossover raise for a round of new drug/device CNS clinical trials

A Seattle-based drug/device company with its own particular approach for getting drugs delivered into the brain through the nose has put together a top-notch syndicate that’s delivered $67.5 million in Series D cash.